UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 451

Sortiert nach

Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double‐blind, randomized, parallel‐group, multicenter study

Epilepsia (Copenhagen), 2018-02, Vol.59 (2), p.479-491

2018

Volltextzugriff (PDF)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease

Movement disorders, 2022-11, Vol.37 (11), p.2272-2283

2022

Volltextzugriff (PDF)

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers

Molecular nutrition & food research, 2009-05, Vol.53 (S1), p.S7-S15

2009

Volltextzugriff (PDF)

Population Pharmacokinetic‐Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS)

Journal of clinical pharmacology, 2020-05, Vol.60 (5), p.617-628

2020

Volltextzugriff (PDF)

Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

Epilepsia (Copenhagen), 2013-01, Vol.54 (1), p.108-116

2013

Volltextzugriff (PDF)

Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474

British journal of pharmacology, 2020-05, Vol.177 (9), p.2123-2142

2020

Volltextzugriff (PDF)

Inactivation Mechanism of the Fatty Acid Amide Hydrolase Inhibitor BIA 10‐2474

Chembiochem : a European journal of chemical biology, 2022-10, Vol.23 (20), p.e202200166-n/a

2022

Volltextzugriff (PDF)

Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate

Acta neurologica Scandinavica, 2020-05, Vol.141 (5), p.397-404

2020

Volltextzugriff (PDF)

Efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Integrated analysis of pooled data from double‐blind phase III clinical studies

Epilepsia (Copenhagen), 2013-01, Vol.54 (1), p.98-107

2013

Volltextzugriff (PDF)

Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled‐release carbamazepine in noninferiority epilepsy monotherapy trials: How much “fair” is “fair”

Epilepsia (Copenhagen), 2018-04, Vol.59 (4), p.900-901

2018

Volltextzugriff (PDF)

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

Lancet neurology, 2016-02, Vol.15 (2), p.154-165

2016

Volltextzugriff (PDF)

Discovery of a Potent, Long‐Acting, and CNS‐Active Inhibitor (BIA 10‐2474) of Fatty Acid Amide Hydrolase

ChemMedChem, 2018-10, Vol.13 (20), p.2177-2188

2018

Volltextzugriff (PDF)

Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique

Epilepsia (Copenhagen), 2012-03, Vol.53 (3), p.529-538

2012

Volltextzugriff (PDF)

Medicinal Chemistry of Catechol O‑Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility

Journal of medicinal chemistry, 2014-11, Vol.57 (21), p.8692-8717

2014

Volltextzugriff (PDF)

Optimization of a Parallel Artificial Membrane Permeability Assay for the Fast and Simultaneous Prediction of Human Intestinal Absorption and Plasma Protein Binding of Drug Candidates: Application to Dibenz[b,f]azepine-5-Carboxamide Derivatives

Journal of pharmaceutical sciences, 2012-02, Vol.101 (2), p.530-540

2012

Volltextzugriff (PDF)

Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review

Drugs (New York, N.Y.), 2019-04, Vol.79 (6), p.593-608

2019

Volltextzugriff (PDF)

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action

Pharmacology research & perspectives, 2015-03, Vol.3 (2), p.e00124-n/a

2015

Volltextzugriff (PDF)

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study

Epilepsia (Copenhagen), 2009-03, Vol.50 (3), p.454-463

2009

Volltextzugriff (PDF)

Antiepileptogenesis after stroke—trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate

Epilepsia open, 2023-09, Vol.8 (3), p.1190-1201

2023

Volltextzugriff (PDF)

Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects

Journal of clinical pharmacology, 2024-06

2024

Volltextzugriff (PDF)

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial‐onset seizures: Results of a phase III, double‐blind, randomized, placebo‐controlled trial

Epilepsia (Copenhagen), 2015-02, Vol.56 (2), p.244-253

2015

Volltextzugriff (PDF)

Effect of zamicastat on blood pressure and heart rate response to cold pressor test: A double‐blind, randomized, placebo‐controlled study in healthy subjects

British journal of clinical pharmacology, 2024-07

2024

Volltextzugriff (PDF)

Effects of eslicarbazepine on slow inactivation processes of sodium channels in dentate gyrus granule cells

Epilepsia (Copenhagen), 2018-08, Vol.59 (8), p.1492-1506

2018

Volltextzugriff (PDF)

Complex effects of eslicarbazepine on inhibitory micro networks in chronic experimental epilepsy

Epilepsia (Copenhagen), 2021-02, Vol.62 (2), p.542-556

2021

Volltextzugriff (PDF)

Renal amino acid transport systems and essential hypertension

The FASEB journal, 2013-08, Vol.27 (8), p.2927-2938

2013

Volltextzugriff (PDF)

1 – 25 von 451

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(434)
Mit Volltextzugriff
(414)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double‐blind, randomized, parallel‐group, multicenter study

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers

Population Pharmacokinetic‐Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS)

Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474

Inactivation Mechanism of the Fatty Acid Amide Hydrolase Inhibitor BIA 10‐2474

Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate

Efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Integrated analysis of pooled data from double‐blind phase III clinical studies

Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled‐release carbamazepine in noninferiority epilepsy monotherapy trials: How much “fair” is “fair”

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

Discovery of a Potent, Long‐Acting, and CNS‐Active Inhibitor (BIA 10‐2474) of Fatty Acid Amide Hydrolase

Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique

Medicinal Chemistry of Catechol O‑Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility

Optimization of a Parallel Artificial Membrane Permeability Assay for the Fast and Simultaneous Prediction of Human Intestinal Absorption and Plasma Protein Binding of Drug Candidates: Application to Dibenz[b,f]azepine-5-Carboxamide Derivatives

Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study

Antiepileptogenesis after stroke—trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate

Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial‐onset seizures: Results of a phase III, double‐blind, randomized, placebo‐controlled trial

Effect of zamicastat on blood pressure and heart rate response to cold pressor test: A double‐blind, randomized, placebo‐controlled study in healthy subjects

Effects of eslicarbazepine on slow inactivation processes of sodium channels in dentate gyrus granule cells

Complex effects of eslicarbazepine on inhibitory micro networks in chronic experimental epilepsy

Renal amino acid transport systems and essential hypertension

Suchergebnisse filtern